Prediction of Resistance to 177Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers

[Shorehousejam]

jnm.snmjournals.org/content...

”Taken together, despite these limitations, the role of ctDNA as a biomarker for response when using 177Lu-PSMA–based therapies is important to assess. Such analyses are important in the prognosis for a variety of cancers and a variety of treatments. The alterations identified here seem plausible on the basis of outcomes in other cancers and when using other therapies. Clearly, larger studies are justified to better understand the relationships between PSMA-targeted radioligand therapy and somatic genetics as assessed by ctDNA.”

[God_Loves_Me]

I hope dose escalations help us. Great results from Phase II

urotoday.com/conference-hig...